

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS PO. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/021,294	12/19/2001	Suzie Hwang Pun	038134-5006	9341
28120	7590 05/20/2003			
ROPES & GRAY LLP			EXAMINER	NER
ONE INTERNATIONAL PLACE BOSTON, MA 02110-2624			MAIER, LEIGH C	
			ART UNIT	PAPER NUMBER
			1623	. 10
•			DATE MAILED: 05/20/2003	•

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No. 10/021,294 Applicant(s)

Pun

Examiner

Leigh Maier

Art Unit 1623



	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address		
	or Reply	,		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the				
- If the p - If NO p - Failure - Any re	date of this communication.  eriod for reply specified above is less than thirty (30) days, a reply within the riod for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6) MONTHS from the mailing date of this communication. ne application to become ABANDONED (35 U.S.C. § 133).		
Status				
1) 🗆	Responsive to communication(s) filed on	<u> </u>		
2a) 🗌	This action is <b>FINAL</b> . 2b) 💢 This act	ion is non-final.		
3) 🗆	Since this application is in condition for allowance $\epsilon$ closed in accordance with the practice under $\epsilon x$ particles.	except for formal matters, prosecution as to the merits is rte Quayle, 1935 C.D. 11; 453 O.G. 213.		
Disposit	ion of Claims			
4) 💢	Claim(s) <u>1-10</u>	is/are pending in the application.		
4	a) Of the above, claim(s)	is/are withdrawn from consideration.		
5) 🗆	Claim(s)	is/are allowed.		
	Claim(s)			
_	Claim(s)			
8) 💢	Claims <u>1-10</u>	are subject to restriction and/or election requirement.		
	tion Papers			
9) 🗆	The specification is objected to by the Examiner.			
10)	The drawing(s) filed on is/are	a) $\square$ accepted or b) $\square$ objected to by the Examiner.		
	Applicant may not request that any objection to the d	rawing(s) be held in abeyance. See 37 CFR 1.85(a).		
11)	The proposed drawing correction filed on	is: a) $\square$ approved b) $\square$ disapproved by the Examiner.		
	If approved, corrected drawings are required in reply to	to this Office action.		
12) The oath or declaration is objected to by the Examiner.				
	under 35 U.S.C. §§ 119 and 120			
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a) L	a) All b) Some* c) None of:			
	1. Certified copies of the priority documents have been received.			
		e been received in Application No		
	3. ☐ Copies of the certified copies of the priority deapplication from the International Bureset the attached detailed Office action for a list of the			
14)	Acknowledgement is made of a claim for domestic			
a) [	1			
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.				
Attachm		, , , , , , , , , , , , , , , , , , , ,		
1) 'X No	tice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).		
	tice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)		
3) 🔲 Info	ormation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:		

Application/Control Number: 10/021,294 Page 2

Art Unit: 1623

#### **DETAILED ACTION**

#### Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-4, drawn to compounds as defined by the structural formulas of claims 1 and 3, classified in a large number of classes and subclasses depending of the various segments of the compounds. A modified cyclodextrin according to the recited formulas would be classified in class 536, subclass 103.
- II. Claims 5-10, drawn to polymeric compositions, classified in class 424, subclass489+.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as mutually exclusive species in an intermediate-final product relationship. Distinctness is proven for claims in this relationship if the intermediate product is useful to make other than the final product (MPEP § 806.04(b), 3rd paragraph), and the species are patentably distinct (MPEP § 806.04(h)). The composition claims 5-10 are not really clear, but they appear to be reciting a composition comprising a (1) cyclodextrin-containing polymer; (2) a therapeutic agent; and (3) a complexing agent, which is a compound of claim 1 or claim 3.

In the instant case, when all the variables have a value of zero, a compound of the structural formula of claim 1 can be as simple as an unmodified cyclodextrin. In this case, the intermediate product is deemed to be useful for use in the renaturation of proteins (See Sharma et

Art Unit: 1623

al; US 5,728,804) and the inventions are deemed patentably distinct since there is nothing on this record to show them to be obvious variants. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions anticipated by the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Claims 1-4 and claims 5-10 are generic to a plurality of disclosed patentably distinct species comprising the compounds defined by the structural formulas of claims 1 and 3.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

If Group I is elected, Applicant is required to further select the compounds of claim 1 or claim 3 and designate a value (0 or 1) for each of the variables a, b, x, and y.

If variable a is 1, Applicant must further select a definition for J: (1) non-peptidyl (the first 3 lines of the definition) or (2) peptidyl (the last 4 lines of the definition).

Art Unit: 1623

If variable b is 1, Applicant must further select a definition of L: (1) a carbohydrate residue or (2) the balance of the recited definition.

Finally, Applicant must further select a single host or guest.

If Group II is elected, Applicant must select the composition of claim 5 or claim 8 in addition to (1) a single complexing agent and (2) a class of therapeutic agents.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1623

### Examiner's hours, phone & fax numbers

Page 5

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leigh Maier whose telephone number is (703) 308-4525. The examiner can normally be reached on Monday-Friday 7:00 to 3:30 (ET).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson (703) 308-4624, may be contacted. The fax phone number for Group 1600, Art Unit 1623 is (703) 308-4556 or 305-3592.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-1235.

Visit the U.S. PTO's site on the World Wide Web at http://www.uspto.gov. This site contains lots of valuable information including the latest PTO fees, downloadable forms, basic search capabilities and much more.

Leigh C. Maier Patent Examiner May 16, 2003